Author:
Xu Ruihua,Wang Wei,Zhu Bo,Lin Xiaoyan,Ma Dong,Zhu Lingjun,Zhao Qingchuan,Nie Yongzhan,Cai Xiaohong,Li Qi,Fang Weijia,Li Hongyan,Wang Ning,Chen Yun,Peng Cike,Fang Honghao,Shen Lin
Abstract
Abstract
Background
Colorectal cancer (CRC) is the third most prevalent cancer in China but few large-scale studies were conducted to understand CRC patients. The current study is aimed to gain a real-world perspectives of CRC patients in China.
Methods
Using electronic medical records of sampled patients between 2011 and 2016 from 12 hospitals in China, a retrospective cohort study was conducted to describe demographics and disease prognosis of CRC patients, and examine treatment sequences among metastatic CRC (mCRC) patients. Descriptive, comparative and survival analyses were conducted.
Results
Among mCRC patients (3878/8136, 48%), the fluorouracil, leucovorin, and oxaliplatin (FOLFOX) and other oxaliplatin-based regimens were the most widely-used first-line treatment (42%). Fluorouracil, leucovorin, irinotecan (FOLFIRI) and other irinotecan-based regimens dominated the second-line (40%). There was no a dominated regimen for the third-line. The proportion of patients receiving chemotherapy with targeted biologics increased from less than 20% for the first- and second- lines to 34% for the third-line (p < 0.001). The most common sequence from first- to second-line was from FOLFOX and other oxaliplatin-based regimens to FOLFIRI and other irinotecan-based regimens (286/1200, 24%).
Conclusions
Our findings reflected a lack of consensus on the choice of third-line therapy and limited available options in China. It is evident o continue promoting early CRC diagnosis and to increase the accessibility of treatment options for mCRC patients. As the only nationwide large-scale study among CRC and mCRC patients before more biologics became available in China, our results can also be used as the baseline to assess treatment pattern changes before and after more third-line treatment were approved and covered into the National Health Insurance Plan in China between 2017 and 2018.
Funder
Lilly Suzhou Pharmaceutical Company Limited
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference40 articles.
1. Chen W, Zheng R, Zhang S, Zhao P, Zeng H, Zou X. Report of cancer incidence and mortality in China, 2010. Ann Transl Med. 2014 Jul;2(7):61.
2. Du LB, Li HZ, Wang YQ, Zhu C, Zheng RS, Zhang SW, Chen WQ, He J. Report of colorectal cancer incidence and mortality in China, 2013. Zhonghua Zhong Liu Za Zhi. 2017 Sep;39(9):701–6.
3. Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009 Nov;22(04):191–7.
4. Correa Lima MP, Gomes-da-Silva MH. Colorectal cancer: lifestyle and dietary factors. Nutr Hosp. 2005;20(4):235–41.
5. Zeng H, Zheng R, Guo Y, Zhang S, Zou X, Wang N, Zhang L, Tang J, Chen J, Wei K, Huang S. Cancer survival in C hina, 2003–2005: a population-based study. Int J Cancer. 2015 Apr 15;136(8):1921–30.
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献